OMERS ADMINISTRATION Corp Takes Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

OMERS ADMINISTRATION Corp acquired a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 65,045 shares of the biopharmaceutical company's stock, valued at approximately $362,000. OMERS ADMINISTRATION Corp owned 0.15% of Abeona Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Northern Trust Corp boosted its holdings in Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after purchasing an additional 11,478 shares during the period. Oxford Asset Management LLP bought a new stake in Abeona Therapeutics in the 4th quarter valued at about $118,000. JPMorgan Chase & Co. boosted its holdings in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 28,606 shares during the period. Balyasny Asset Management L.P. bought a new stake in Abeona Therapeutics in the 4th quarter valued at about $190,000. Finally, Bank of America Corp DE boosted its holdings in Abeona Therapeutics by 16.7% in the 4th quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company's stock valued at $1,473,000 after purchasing an additional 37,774 shares during the period. Institutional investors own 80.56% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Stifel Nicolaus reduced their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, May 16th. HC Wainwright lifted their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Finally, Oppenheimer started coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $18.50.

Insiders Place Their Bets

In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the transaction, the chief executive officer now owns 1,355,322 shares in the company, valued at $6,478,439.16. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark Alvino sold 8,000 shares of Abeona Therapeutics stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $5.68, for a total value of $45,440.00. Following the completion of the transaction, the director now owns 92,435 shares in the company, valued at $525,030.80. This trade represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is currently owned by corporate insiders.

Abeona Therapeutics Trading Down 2.4%

NASDAQ:ABEO traded down $0.16 during midday trading on Friday, hitting $6.42. 957,198 shares of the company traded hands, compared to its average volume of 619,860. The firm has a market capitalization of $328.43 million, a P/E ratio of -2.39 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 12-month low of $3.93 and a 12-month high of $7.32. The firm's fifty day moving average is $5.29 and its 200-day moving average is $5.55.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. On average, sell-side analysts predict that Abeona Therapeutics Inc will post -1.16 EPS for the current year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.